Introduction
Neuropathic pain, caused by a lesion or disease aff ecting the somatosensory nervous system, 1 has a substantial eff ect on quality of life and is associated with a high economic burden for the individual and society. [2] [3] [4] It is now regarded as a distinct clinical entity despite a large variety of causes. 5 Epidemiological surveys have shown that many patients with neuropathic pain do not receive appropriate treatment. 2, 6, 7 The reasons might be low diagnostic accuracy and ineff ective drugs, and perhaps also insuffi cient knowledge about eff ective drugs and their appropriate use in clinical practice. 8 Evidence-based recommendations for the pharmacotherapy of neuropathic pain are therefore essential. Over the past 10 years, a few recommendations have been proposed for the pharmacotherapy of neuropathic pain [9] [10] [11] or specifi c neuropathic pain disorders, particularly painful diabetic neuropathies and post-herpetic neuralgia.
12-14 Meanwhile, new pharmacological therapies have been developed and high-quality clinical trials have been done. Previously undisclosed and unpublished large trials can now be identifi ed online (ClinicalTrials. gov and pharmaceutical industry websites), which, together with an analysis of publication bias, might reduce the risk of bias in reporting data. Furthermore, there were some discrepancies in previous recommendations due to inconsistencies in methods used to assess the quality of evidence. 13, 15, 16 To address these inconsistencies, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was introduced in 2000 17, 18 and received widespread international acceptance. Together, these reasons justify an update of the evidence-based recommendations for the pharmacotherapy of neuropathic pain.
We did a systematic review and meta-analysis of randomised controlled trials of all drug treatments for neuropathic pain published since 1966 and of unpublished trials with available results, and assessed publication bias. We used GRADE to rate the quality of evidence and the strength of recommendations. 17, 18 On the basis of the updated review and meta-analysis, we revised the recommendations of the Special Interest Group on Neuropathic Pain (NeuPSIG) of the International Association for the Study of Pain for the systemic and topical pharmacological treatment of neuropathic pain. 19 Non-pharmacological management strategies such as neurostimulation techniques were beyond the scope of this work. 20 
Methods

Search strategy and selection criteria
We followed the 23-item Appraisal of Guidelines for Research and Evaluation (AGREE II) for developing and reporting recommendations. 21 For details of the working group, criteria for eligibility of studies for the analysis, search methods, reporting, and statistical analysis, see the appendix.
The systematic review of the literature complied with the PRISMA statement. 22 We used a standardised review and data extraction protocol (unpublished, appendix). The full reports of randomised, controlled, double-blind studies published in peer-reviewed journals between January, 1966, and April, 2013, were identifi ed with searches of PubMed, Medline, the Cochrane Central Register of Controlled Trials, and Embase. Additional papers were identifi ed from published reviews and the reference lists of selected papers. Studies reporting results were searched in all primary registries in the WHO Registry Network and in registries approved by the International Committee of Medical Journal Editors in April, 2013 (appendix). Only ClinicalTrials.gov had relevant data. An additional search up to Jan 31, 2014, retrieved papers from PubMed and the ClinicalTrials.gov website. Data from a search in May, 2009, of the Pharmaceutical Research and Manufacturers of America (PhRMA) clinical study results website were also included. 23 The target population was patients of any age with neuropathic pain according to the International Association for the Study of Pain defi nition (ie, pain caused by a lesion or disease of the somatosensory nervous system):
1 post-herpetic neuralgia, diabetic and non-diabetic painful polyneuropathy, post-amputation pain, post-traumatic or post-surgical neuropathic pain including plexus avulsion and complex regional pain syndrome type 2 (which was generally subsumed into post-traumatic or post-surgical neuropathic pain), central post-stroke pain, spinal cord injury pain, and multiplesclerosis-associated pain. Neuropathic pain pertaining to diff erent causes was also included. Neuropathic pain associated with nociceptive components (eg, neuropathic cancer-related pain and radiculopathy) was included if the primary outcome of the study was related to neuropathic pain. Disorders such as complex regional pain syndrome type 1, low back pain without radicular pain, fi bromyalgia, and atypical facial pain were not included because they do not meet the current defi nition of neuropathic pain. 1 Trigeminal neuralgia was assessed separately because the response to drug treatment was generally distinct from other neuropathic pain. 10, 24 The interventions were systemic or topical treatments (oral, sublingual, oropharyngeal, intranasal, topical, subcutaneous, intradermal, and smoking) with at least 3 weeks of treatment. Single-administration treatments with long-term effi cacy (high-concentration capsaicin patches and botulinum toxin) were included if there was a minimum follow-up of 3 weeks. Studies in which intramuscular, intravenous, or neuroaxial routes of administration were used and those of pre-emptive analgesia were excluded (for details, see Dworkin and colleagues 20 ). We included randomised, double-blind, placebocontrolled studies with parallel group or crossover study designs that had at least ten patients per group. We separately summarised enriched-enrolment, randomised withdrawal trials. We excluded studies published only as abstracts and included double-blind, active comparator trials of drugs generally proposed as fi rst-line or secondline treatments. 23 The study outcome (positive or negative) was based on the eff ect on the primary outcome measureeg, neuropathic pain intensity. We excluded studies in which the primary outcome included a composite score of pain and paraesthesia or paraesthesia only.
Five investigators (SH, EM, KL, NBF, and NA) assessed studies for methodological quality by using the fi ve-point Oxford Quality Scale (appendix). 25 A minimum score of 2 of 5 (randomised and double-blind study) was required for inclusion. 25 We also assessed the serious risk of bias relating to absence of allocation concealment, incomplete accounting of outcome events, selective outcome reporting, stopping early for benefi t, use of invalidated outcome measures, and carryover eff ects in crossover trials.
Evidence summary and reporting
The GRADE classifi cation was used to assess recommendations based on the results from a group of randomised controlled trials of the same drug or drug class when relevant (eg, tricyclic antidepressants), 17, 18 with fi nal quality of evidence rated as strong or weak for the treatment, strong or weak against the treatment, or inconclusive (the last category was added because of the large number of inconsistent results in randomised controlled trials). We did not do a new health economic analysis of costs, 16 but estimated three levels of drug costs in various countries in relation to the average price of oral drugs for each country using price data for the daily dose as defi ned by WHO (appendix). The mean of these percentages for the countries was calculated, and the cost was rated as low if it was less than 67%, moderate if 67-300%, and high if more than 300% of the mean across all drugs. The fi nal recommendations were agreed on by consensus of the authors.
Statistical analysis
Number needed to treat (NNT) for 50% pain intensity reduction (or 30% pain reduction or at least moderate pain relief) was the primary eff ect measure, and the number needed to harm (NNH) was calculated as the number of patients who needed to be treated for one patient to drop out because of adverse eff ects. The 95% CIs for NNT and NNH were calculated as the reciprocal values of the 95% CIs for the absolute risk diff erence by use of the normal approximation. In dose-fi nding studies, data from subgroups treated with low doses (eg, pregabalin 150 mg) were not included in the meta-analysis. Diff erence in pain intensity was a secondary outcome. Serious and common (>10% incidence) adverse events were recorded on the data extraction form (appendix).
We used funnel plots, 26 Egger's regression, 27 and Duval and Tweedie's non-parametric trim-and-fi ll approach 28 to assess publication bias (appendix). Additionally, we estimated the susceptibility to bias for individual drug classes. 29, 30 The extent to which the variability (heterogeneity) in treatment eff ects is explained by publication in a peer-reviewed journal was assessed with meta-regression. Heterogeneity in trials was presented as a L'Abbé plot 31 and as the I² statistic.
Role of the funding source
NA, NBF, PRK, RB, ASCR, MH, SNR, and BHS are members of the NeuPSIG management committee and had a role in study design, data gathering, data analysis, data interpretation, and the writing of the report. The corresponding author and all co-authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the results of the database and registry search. 191 published reports and 21 unpublished studies were included in the quantitative synthesis. Study characteristics are summarised in the appendix. Additionally, fi ve published and 12 unpublished studies were retrieved between April, 2013, and January, 2014. Thus, a total of 229 reports or studies were included (see appendix for details of the references).
Results
In studies eligible for inclusion in the meta-analysis, the following drugs were investigated: tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitor antidepressants, other antidepressants, pregabalin, gabapentin or gabapentin extended release and enacarbil, other antiepileptics, tramadol, opioids, cannabinoids, lidocaine 5% patch, capsaicin highconcentration patch and cream, botulinum toxin A, NMDA antagonists, mexiletine, miscellaneous topical treatments, newer systemic drugs, and combination therapies. 127 (55%) of 229 trials were done in patients with diabetic painful polyneuropathy or post-herpetic neuralgia. NNT and NNH could be calculated in 176 (77%) of 229 published placebo-controlled trials.
The Oxford Quality Scale (Jadad) scores for individual trials are presented in the appendix. The mean score was 4•1 (SD 0•87, range 2-5). It was lower for older studies of tricyclic antidepressants and capsaicin (3-4) and higher for more recent studies of pregabalin, gabapentin, serotonin-noradrenaline reuptake inhibitors, opioids, and capsaicin high-concentration patches (>4). Detailed descriptions of the limitations of individual studies are available from the corresponding authors on request. Figures 2 and 3 show the NNT for individual studies for drugs with strong recom mendation for use (see the susceptibility to publication bias in individual drug classes. Only the estimated eff ect size of capsaicin 8% patches showed susceptibility to change to a clinical non-signifi cant eff ect if studies with no eff ect were published. Using meta-regression, we identifi ed that for studies published in peer-reviewed journals the
Combined (fixed effects)
PHN, gabapentin enacarbil 1200 mg and 2400 mg and 3600 mg, NCT00619476, Zhang et al ( reported treatment eff ects were greater (2•2, 1•5-3•0, n=153; adjusted r² 9•3%, p=0•009) than were those for studies identifi ed through online repositories (1•4,
The results of individual and combined NNT and NNH for placebo-controlled studies are presented in the appendix, along with other studies, quality of evidence, and risk diff erences calculated with fi xed-eff ect and random-eff ects models. Generally, there was no evidence of diff erent effi cacies for most drugs in distinct neuropathic pain disorders (fi gures 2, 3; appendix). Few studies lasted longer than 12 weeks, with the longest lasting 24 weeks.
In 18 placebo-controlled trials (20 comparisons with placebo, of which seven comparisons had active placebos; 12 trials assessed amitriptyline [25-150 mg/day]), 16 comparisons were positive. The fi nal quality of evidence was moderate (appendix). There was no evidence of a dose-response eff ect. Combined NNT for 15 studies was 3•6 (95% CI 3•0-4•4) and NNH was 13•4 (9•3-24•4).
We identifi ed 14 studies of serotonin-noradrenaline reuptake inhibitors with available results: nine with duloxetine (20-120 mg, seven positive), four with venlafaxine (doses 150-225 mg/day, two positive, and two negative with low doses), one with desvenlafaxine (negative; appendix). The fi nal quality of evidence was high. Combined NNT was 6•4 (5•2-8•4) and NNH was 11•8 (9•5-15•2).
18 of 25 placebo-controlled randomised trials of pregabalin (150-600 mg/day) were positive, with high fi nal quality of evidence (appendix). There was a doseresponse gradient (higher response with 600 mg daily than with 300 mg daily; data not shown). Two trials of HIV-related painful polyneuropathy with high placebo responses were negative (34% and 43% had 50% pain relief with placebo). Combined NNT was 7•7 (95% CI 6•5-9•4) and NNH was 13•9 (11•6-17•4).
We identifi ed 14 randomised controlled trials of gabapentin (900-3600 mg/day; nine positive) and six of gabapentin extended release or gabapentin enacarbil (1200-3600 mg/day; four positive). Data are number, unless otherwise indicated. *Number of comparisons with placebo in published trials and unpublished trials included in the meta-analysis; results from registries were included if they reported numbers of responders. †Total number of patients treated with active treatment and placebo; patients were counted twice if the study had a crossover design. ‡Number of patients needed to be treated in a new study showing no eff ect to make the number needed to treat (NNT) greater than 11, which is the cutoff for clinical relevance; susceptibility to publication bias implies that a new study with fewer than 400 participants with no eff ect might increase the NNT to greater than 11. §Including gabapentin extended release and enacarbil. ¶Susceptible to publication bias. Most studies with other antiepileptic drugs were negative. Topiramate, zonisamide, and oxcarbazepine or carbamazepine had the poorest safety profi les, with a combined NNH of 6•3 (95% CI
Tramadol is a weak opioid agonist and a serotoninnoradrenaline reuptake inhibitor. All seven studies of tramadol (mainly tramadol extended release up to 400 mg/day) were positive, with moderate fi nal quality of evidence (appendix). Combined NNT was 4•7 (95% CI 3•6-6•7), with the highest NNT (6•4) in the largest study (appendix). Combined NNH was 12•6 (8•4-25•3).
Tapentadol is a μ opioid agonist with noradrenaline reuptake inhibition. We identifi ed one negative study and one positive enrichment study of tapentadol extended release; the study of the extended release formulation had potential bias (probable unmasking of the patients enrolled in the double-blind period) and high NNT (10·2, 95% CI 5·3-185·5) in 67% of the patients responding to the open phase.
We identifi ed 13 trials of strong opioids, in which oxycodone (10-120 mg/day) and morphine (90-240 mg/day) were used mainly in peripheral neuropathic pain. The fi nal quality of evidence was moderate. Ten trials were positive: combined NNT was 4•3 (95% CI 3•4-5•8) and NNH was 11•7 (8•4-19•3) . Maximum eff ectiveness seemed to be associated with 180 mg morphine or equivalent (no additional benefi t for higher doses; appendix). Nabiximols (Sativex) is an oromucosally delivered spray prepared from extracts of the plant cannabis sativa with several active constituents (mainly standardised 27 mg/mL Δ-9-tetrahydrocannabinol and 25 mg/mL cannabidiol). We identifi ed nine trials of nabiximols in neuropathic pain, of which only two were positive. One of these two studies of pain associated with multiple sclerosis was positive, whereas the other larger study had a negative primary outcome.
Based on our inclusion criteria (trials of at least 3 weeks), we identifi ed only one small negative study of 5% lidocaine patches in post-surgical neuropathic pain and two enriched-enrolment studies in post-herpetic neuralgia. The smaller study was positive; the larger study was negative in the intention-to-treat population, but positive in the per-protocol population. However, studies of shorter duration were positive, and safety and tolerability were good in all cases. 23 The results of fi ve of seven studies (in patients with post-herpetic neuralgia or HIV-related painful polyneuropathy) showed sustained effi cacy of a single application of high-concentration capsaicin patch (8%, better results for 60 min application in post-herpetic neuralgia and 30 min in HIV neuropathy) compared with a low-concentration patch (0·04%, to minimise the risk of unmasking related to the burning sensation of capsaicin). GRADE=Grading of Recommendations Assessment, Development, and Evaluation (see appendix for details about the GRADE classifi cation). *Duloxetine is the most studied, and therefore recommended, of the serotonin-noradrenaline reuptake inhibitors. †Tricyclic antidepressants generally have similar effi cacy (appendix); tertiary amine tricyclic antidepressants (amitriptyline, imipramine, and clomipramine) are not recommended at doses greater than 75 mg/day in adults aged 65 years and older because of major anticholinergic and sedative side-eff ects and potential risk of falls; 33 an increased risk of sudden cardiac death has been reported with tricyclic antidepressants at doses greater than 100 mg daily. 34 ‡The long-term safety of repeated applications of high-concentration capsaicin patches in patients has not been clearly established, particularly with respect to degeneration of epidermal nerve fi bres, which might be a cause for concern in progressive neuropathy. §Sustained release oxycodone and morphine have been the most studied opioids (maximum doses of 120 mg/day and 240 mg/day, respectively, in clinical trials; appendix); long-term opioid use might be associated with abuse, particularly at high doses, cognitive impairment, and endocrine and immunological changes. [35] [36] [37] The fi nal quality of evidence was high. Combined NNT was 10·6 (95% CI 7·4-18·8). Results for the secondary outcomes were inconsistent (data not shown).
Total daily dose and dose regimen Recommendations
Strong recommendations for use
Six randomised controlled trials to assess the effi cacy of a single administration of botulinum toxin A (50-200 units, subcutaneously, in the region of pain) in peripheral neuropathic pain were identifi ed. The smaller studies had a positive primary outcome (NNT 1·9, 95% CI 1·5-2·4, for four studies) with a low placebo eff ect, but one large, unpublished study was negative. Safety was generally good (appendix).
Results for other drugs (selective serotonin reuptake inhibitor antidepressants, capsaicin cream, NMDA antagonists, Δ-9-tetrahydrocannabinol, mexiletine, and newer topical or oral drugs) are reported in the appendix. There were no randomised controlled trials with conventional non-opioid analgesics (non-steroidal antiinfl ammatory drugs or acetaminophen).
Of seven randomised controlled trials of various combination therapies in neuropathic pain (appendix), the results of two showed that gabapentin combined with morphine or nortriptyline was superior to drugs given as monotherapies (and placebo in one study) at reduced doses, with no more side-eff ects. However, the results of the largest study (not placebo controlled) showed no diff erence in effi cacy or side-eff ects between pregabalin combined with duloxetine at moderate doses (300 mg/day and 60 mg/day, respectively) and pregabalin and duloxetine monotherapies at high doses (600 mg/day and 120 mg/day, respectively) in patients unresponsive to monotherapy at moderate doses.
We identifi ed seven comparative randomised controlled trials without placebo (appendix). Neither individual studies nor their statistical combination showed signifi cant diff erences in effi cacy or safety between drugs. Despite small sample sizes and unknown assay sensitivity because of the absence of a placebo, results suggested similar effi cacy for fi rst-line and most secondline recommended treatments.
There was generally no evidence of effi cacy for particular drugs in specifi c disorders. Therefore, these recommendations apply to neuropathic pain in general. However, they might not be applicable to trigeminal neuralgia, for which we could extract only one study complying with our inclusion criteria. We therefore recommend referring to previous specifi c guidelines for this disorder. 10, 24 Few studies included cancer-related neuropathic pain; the recommendations for the use of opioids might be diff erent in certain cancer populations. Similarly, these recommendations do not apply to acute pain or acute pain exacerbation. Treatment of neuropathic pain in children is neglected. 32 None of the studies assessed paediatric neuropathic pain and therefore the current guidelines only apply to adults.
Details of the GRADE recommendations and practical use are provided in table 2, the panel, table 3, and the appendix. A few relevant trials have been reported since our meta-analysis, but none aff ected the recommendations (appendix). Based mainly on moderate or high quality of evidence and effi cacy in most trials, tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitor antidepressants (particularly duloxetine), pregabalin, gabapentin, gabapentin extended release and enacarbil have strong GRADE recommendations for use in neuropathic pain and are proposed as fi rst-line treatments, with caution recommended for several tricyclic antidepressants at high doses (table 2) . Tramadol, lidocaine patches, and high-concentration capsaicin patches have weak GRADE recommendations for use and are proposed as generally second line because of lower tolerability or safety (tramadol), and low eff ect sizes but high values or preferences and tolerability or safety (topical agents). Topical treatments are recommended for peripheral neuropathic pain with presumed local pain GRADE=Grading of Recommendations Assessment, Development, and Evaluation (see appendix for details about the GRADE classifi cation). *Common side-eff ects: antidepressants: somnolence, constipation, dry mouth (particularly with tricyclic antidepressants), and nausea (particularly duloxetine); pregabalin or gabapentin: somnolence, dizziness, and weight gain; opioids (including tramadol): constipation, nausea, vomiting, tiredness, somnolence, dizziness, dry mouth, and itch; lidocaine patches: local irritation; capsaicin patches: local pain, oedema, and erythema; botulinum toxin A: local pain; see the appendix for further information about safety issues. generator, such as post-herpetic neuralgia, post-traumatic painful neuropathies, and painful polyneuropathies. In some circumstances-eg, when there are concerns because of side-eff ects or safety of fi rst-line treatments, particularly in frail and elderly patients-lidocaine patches might be a fi rst-line option. Strong opioids (particularly oxycodone and morphine) and botulinum toxin A (specialist use for peripheral neuropathic pain with presumed local pain generator) have weak GRADE recommendations for use and are recommended as third line mainly because of safety concerns (opioids) or weak quality of evidence (botulinum toxin A). Prescription of strong opioids should be strictly monitored, particularly for patients requiring high doses (including tracking the dose in morphine equivalence, use of risk assessment methods and treatment agreements). 38, 39 The GRADE recommendations for tapentadol, other antiepileptics, capsaicin cream, topical clonidine, selective serotonin reuptake inhibitor antidepressants, NMDA antagonists, and combination therapy [40] [41] [42] are inconclusive mainly because of discrepant fi ndings. However, the combination of pregabalin or gabapentin and duloxetine or tricyclic antidepressants might be an alternative option to increasing doses of monotherapy for patients unresponsive to moderate doses of monotherapy (see appendix for details).
Cannabinoids and valproate have weak recommendations against their use in neuropathic pain and levetiracetam and mexiletine have strong recommendations against their use because of generally negative trials or safety concerns, or both (see appendix for details).
Discussion
In accordance with previous reports, 23 results of our meta-analysis show that the effi cacy of systemic drug treatments is generally not dependent on the cause of the underlying disorder (appendix). Side-eff ects might, however, to some degree depend on the cause-eg, drugs with CNS-related side-eff ects might be tolerated less well in patients with CNS lesions. 43 Pain due to HIV-related painful polyneuropathy and radiculopathy seems more refractory than other types of pain in our meta-analysis. This diff erence might be due to large placebo responses in HIV-related neuropathy trials, 44 a distinct clinical phenotype in subgroups of patients with radiculopathy, 45 or psychological or psychosocial comorbidities, often neglected in large trials. Topical agents have no known relevance for use in central pain, and this is clearly stated in our recommendations.
The strengths of this systematic review and metaanalysis include the analysis of publication bias 29 and unpublished trials. Publication bias can occur if studies with positive results are published whereas those with no data or negative results are not. 29 It might lead to a major overestimation of effi cacy in therapeutic studies. 46 Our results show that the eff ect sizes estimated from studies published in peer-reviewed journals were higher than those estimated from studies available in open databases. This fi nding emphasises the need to search these databases in systematic reviews. Analysis of further publication bias (eg, studies that are unpublished or show no results in open trial registries) suggested a small overstatement of overall effi cacy of drug treatments (by about 10%), although available methods to assess publication bias have limitations. 47 Here, we found that high-concentration capsaicin patches were the most susceptible to publication bias-ie, a new study with fewer than 400 participants with no eff ect can increase the NNT to an unacceptable level. This fi nding lends support to the robustness of a meta-analysis that includes unpublished trials and suggests that eff ect sizes were overestimated in previous meta-analyses of pharmacotherapy for neuropathic pain.
Results of quantitative data for individual drugs, showing NNT for 50% pain relief ranging from about 4 to 10 for most positive trials, emphasise the modest overall study outcomes in neuropathic pain. Inadequate response to drug therapy constitutes a substantial unmet need in patients with neuropathic pain and might have important consequences in terms of psychological or social adjustment. 48 However, our results might also indicate insuffi cient assay sensitivity in clinical trials of neuropathic pain (table 4) . 55 One major issue is the placebo response, which seems to have increased in recent trials of neuropathic pain and can lead to an underestimation of drug eff ects. 56 Placebo response was higher in HIV-related neuropathies, 44 and in patients with low or variable pain scores at inclusion. 54 Conversely, it seems to be lower in post-herpetic neuralgia. 44 Another issue is the
NeuPSIG recommendation for future trials in neuropathic pain
Patient population (appendix)
All randomised controlled trials were in adults Do more studies in the paediatric population Absence of validated diagnostic criteria and algorithms for neuropathic pain Use NeuPSIG diagnostic criteria for probable or defi nite neuropathic pain and validated screening tools to confi rm diagnosis* Classifi cation of patients is generally based on the cause of the pain Classifi cation should be based on sensory phenotypes rather than merely on the cause of the pain †
Characteristics of the trials (appendix)
Trial duration is 12 weeks or less in 81% of the trials Consider longer trial duration
High placebo response, particularly in recent trials Exclude patients with low pain intensity and high variability of pain at baseline 44 NeuPSIG=Special Interest Group on Neuropathic Pain. *Criteria for neuropathic pain diagnosis were not available before the development of the screening methods and of diagnostic algorithms for neuropathic pain (2008); 49, 50 less than 10% of clinical trials conducted over the past decade have used screening methods or diagnostic algorithms for neuropathic pain (detailed descriptions of the individual studies are available on request). †Results of recent clinical trials 51, 52 and post-hoc analyses of recent clinical trials 53 that could not be included in the present meta-analysis lend support to this recommendation; the results of some trials suggested that drugs such as oxcarbazepine or topical clonidine might be signifi cantly more eff ective in subgroups of patients with preserved nociceptive function compared with those without this phenotype, 54, 49 but these individual trials need to be replicated and do not change the current level of recommendation for these drug treatments. and screening methods 50 should contribute to a reduction in diagnostic heterogeneity (table 4) . Additionally, a largely debated issue is the heterogeneity of patients' phenotypes in clinical trials, which might indicate various underlying mechanisms. [57] [58] [59] The results of some recent trials or posthoc analyses of recent trials suggest that some drugs might be diff erentially eff ective in patients classifi ed according to their sensory phenotypes. [51] [52] [53] Like previous NeuPSIG recommendations, 19 the current recommendations are determined by drug treatments rather than by the cause of pain. Our updated therapeutic algorithm for neuropathic pain based on GRADE diff ers in several ways from previous therapeutic recommendations. The previous recommendations generally proposed tricyclic antidepressants, pregabalin, gabapentin, and lidocaine patches as fi rst line for neuropathic pain. [9] [10] [11] [12] [13] [15] [16] 19, 60 We now also recommend gabapentin extended release or enacarbil, and duloxetine as fi rst line based on strong GRADE recommendations for use. We no longer propose lidocaine patches as fi rst line because of weak quality of evidence. However, because of the excellent safety profi le, high values and preferences, and initial positive short-term studies, we propose lidocaine as a second-line treatment for peripheral neuropathic pain. Strong opioids are now recommended as third line, contrasting with several previous recommendations in which they were generally thought of as fi rst or second line. 19, 60 This stems mainly from the consideration of potential risk of abuse, particularly with high doses, 35 and concerns about a recent increase in prescription-opioid-associated overdose mortality, diversion, misuse, and other opioid-related morbidity particularly in the USA, Canada, and the UK. [61] [62] [63] High-concentration capsaicin patches and cannabinoids are considered for the fi rst time in therapeutic recommendations for neuropathic pain. Capsaicin patches are proposed as second line for peripheral neuropathic pain because of high quality of evidence, but small eff ect size, training requirement, and potential safety concerns on sensation with long-term use. 64 We provide a weak recommendation against the use of cannabinoids in neuropathic pain, mainly because of negative results, potential misuse, diversion, and long-term mental health risks of cannabis particularly in susceptible individuals. [65] [66] [67] [68] [69] [70] One important issue when proposing recommendations is the extent to which they are applied by practitioners and the question of whether the use of recommendations can contribute to improvements in practice. Few studies have investigated the real-life eff ect of evidence-based recommendations on physicians' practices. It has recently been reported that the drug treatment of postherpetic neuralgia by primary care physicians was roughly consistent with the US recommendations issued some years before. 6 By contrast, a recent large study of general practitioners' adherence to current French recommendations noted a paucity of appropriate recall of fi rst-line drugs. 8 It will be important to facilitate the dissemination of the present recommendations and subsequently to assess their real-life implementation in various countries.
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Neuropathic pain aff ects 7-8% of people and will become increasingly common because of the ageing population, increasing incidence of diabetes, and improved survival from c ancer. Unfortunately, neuropathic pain is undertreated and has a large detrimental eff ect on quality of life, partly because of low treatment effi cacy, but also because of ignorance about how best to use available drugs. [1] [2] [3] This issue can hopefully be addressed with accessible evidencebased guidelines. The past decade has not seen any transformational change in management of neuropathic pain, although new treatments have been introduced, existing treatments have been delivered in new ways (eg, topical lidocaine plasters), and studies have tested the effi cacy of combined versus single drug treatments. The report 4 in The Lancet Neurology by Nanna B Finnerup and colleagues (on behalf of the Neuropathic Pain Special Interest Group [NeuPSIG]) provides a timely reappraisal of the evidence base for the pharmacological management of neuropathic pain and generates some pragmatic recommendations.
The meta-analysis 4 includes randomised, doubleblind, placebo-controlled studies of oral or topical analgesic therapy in disorders conforming to the present International Association for the Study of Pain defi nition of neuropathic pain. 5 Strengths of the methods used include estimation of publication bias and the assessment of trial data that are available online but not in peer-reviewed journals (constituting almost 10% of included studies). Perhaps unsurprisingly, studies in peer-reviewed journals showed a greater treatment eff ect than did unpublished studies available online. Finnerup and colleagues estimated that publication bias leads to a 10% overstatement of treatment eff ect (which, with the possible exception of the 8% capsaicin patch, was not predicted to be clinically signifi cant).
Some general conclusions can be drawn: the number needed to treat to achieve 50% pain relief was high (between 4 and 10 in positive trials) and most drugs showed effi cacy across a range of neuropathic pain disorders rather than for specifi c causes. Although combined drug therapy is intellectually appealing as a means to enhance effi cacy and reduce sideeff ects, 6 most studies on this topic have been of relatively small size and one large study did not fi nd a signifi cant diff erence in effi cacy comparing highdose monotherapy (pregabalin or duloxetine) with combined therapy for painful diabetic neuropathy. 7 Because so many patients in clinical practice are on more than one analgesic, more studies are needed in this area. Overall, present options are far from ideal and new and more effi cacious treatments than exist at present are needed for neuropathic pain. The recommendations confi rm expectations in relation to fi rst-line treatments, including tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, gabapentin, gabapentin enacarbil, and pregabalin. The use of topical agents is an emerging theme in neuropathic pain of peripheral origin because they are well tolerated and both lidocaine and high-dose capsaicin patches are recommended as second-line agents along with tramadol. Botulinum toxin A and strong opiates have a weaker recommendation and are considered third-line treatment options. Such recommendations are helpful in prioritisation of treatment choice and I predict that use of strong opiates in neuropathic pain will decline because, although some effi cacy is noted, a growing concern exists over the potential for misuse.
The analysis emphasises some of the challenges facing drug trials in the fi eld of neuropathic pain, including the strong placebo response in pain studies. Several mechanisms are likely to contribute to the generation and maintenance of neuropathic pain-for example, ectopic activity in injured primary aff erents, amplifi cation of nociceptive processing within the spinal cord, microglial activation, and aberrant function of endogenous pain modulatory systems. 8 A key question for the pain fi eld therefore is whether the predominant pathophysiological driver of neuropathic pain can be identifi ed in an individual to allow treatment to be targeted appropriately. This task is challenging. Pathophysiological processes can coexist, their relative importance can change over time, and key outcome measures are needed (eg, assessment of the microglial response in human spinal cord is currently not possible). As a surrogate measure, patients with neuropathic pain can be grouped according to somatosensory phenotype defi ned by symptoms and sensory testing. 9 Such groupings will partly relate to Often, the development of therapeutic approaches for rare disease lags behind that of other disorders not because of poor understanding of the basic pathophysiology, but because of a paucity of systematic clinical information. The ideal way to address this scarcity of clinical knowledge and to facilitate therapeutic advancement is through controlled assessment of large numbers of patients in natural history studies across several institutions.
In The Lancet Neurology, Kathrin Reetz and collegues Using cross-sectional analysis, they produce estimates of progression for each of these measures, which, as expected, are most sensitive for the objective tests, particularly SARA. Interestingly, patients with earlyonset disease progressed fastest, followed by those with intermediate-onset disease, with patients who had late-onset disease progressing more slowly. Such data agree very well with fi ndings from other large cohorts of patients with Friedreich's ataxia, such as the American, Canadian, and Australian FACOMS cohort of more than 750 patients. [2] [3] [4] [5] [6] All of these studies represent underlying pathophysiological mechanisms and the fact that these groups can be noted across diff erent aetiologies of neuropathic pain points to common mechanisms whatever the original cause. Therefore, a strong argument suggests that in future trials patients should be stratifi ed by sensory phenotype so that such groupings can be related to treatment response. Demant and colleagues 10 used such an approach and showed that oxcarbazepine had greater effi cacy in those patients with evidence of gain of sensory function termed the irritable nociceptor than did those patients with predominant loss of sensory function. Although personalised therapy for neuropathic pain is still an aspiration rather than reality, these new NeuPSIG guidelines will help to inform treatment choices, including within the primary care setting, where most patients with neuropathic pain are seen.
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